Compare ICCC & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICCC | VANI |
|---|---|---|
| Founded | 1982 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.1M | 111.0M |
| IPO Year | 1995 | 2014 |
| Metric | ICCC | VANI |
|---|---|---|
| Price | $10.24 | $1.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.83 |
| AVG Volume (30 Days) | 7.6K | ★ 139.0K |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.85 | N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $26,493,169.00 | $4,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $25.72 | ★ N/A |
| Revenue Growth | ★ 51.64 | N/A |
| 52 Week Low | $4.52 | $0.92 |
| 52 Week High | $12.10 | $1.66 |
| Indicator | ICCC | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 56.92 | 41.75 |
| Support Level | $9.45 | $1.10 |
| Resistance Level | $10.82 | $1.25 |
| Average True Range (ATR) | 0.24 | 0.05 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 73.40 | 44.12 |
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.